Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple parts of the body, in 2026.
The announcement follows clearance from the U.S. Food and Drug Administration (FDA) to advance the program into Phase 2.
The study will assess the safety, tolerability, and efficacy of TNX-2900 in male and female participants with Prader-Willi syndrome, aged 8 to 17.5 years.
TNX-2900 has received Orphan Drug and Rare Pediatric Disease designations from the FDA, making it eligible for a potential Priority Review Voucher upon approval.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.